Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Xanthus Life Sciences to Provide Update at the BIO CEO & Investor Conference 2006

    CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced that Richard
T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview
and update on the Company's oncology pipeline at the BIO CEO & Investor
Conference on Tuesday, February 14th at 3:00 pm at The Waldorf-Astoria Hotel
in New York. Dr. Robert L. Capizzi, M.D., F.A.C.P., Senior Vice President and
Chief Medical Officer, will participate in the Revisiting Cytotoxics with New
Molecules Focus Session scheduled on Tuesday, February 14th at 9:00 am, also
at the Waldorf-Astoria Hotel. A live audio webcast of the presentation will be
available on the Company's website located at http://www.xanthus.com. A replay
of the presentation will be posted on the Xanthus website approximately thirty
minutes after the event.

    About Xanthus Life Sciences, Inc.
    Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-
stage, small-molecule oncology candidates through a management team whose
accomplished track record encompasses all aspects of drug development, from
discovery through regulatory approval and commercialization.  The Company is
applying its expertise both to advance its current pipeline and expand it into
indications of unmet medical need beyond oncology.
    Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.

    Contacts:
     Kari Watson, MacDougall Biomedical Communications, Inc. -
kwatson@macbiocom.com or (508) 647-0209
     John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences,
Inc. - john.mccarthy@xanthus.com or (617) 225-0522, x 125


SOURCE Xanthus Life Sciences, Inc.




Back to Topback to top

Related links:
  • http://www.xanthus.com
    CONTACT:
    Kari Watson of MacDougall Biomedical
    Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
    John A. McCarthy, Jr., Senior Vice President & CFO of Xanthus
    Life Sciences, Inc., +1-617-225-0522, ext. 125,
    john.mccarthy@xanthus.com